PROKIDNEY CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.39 USD | +6.70% |
|
+15.74% | +34.27% |
| Mar. 25 | ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations | CI |
| Mar. 22 | ProKidney Posts Wider 2023 Loss | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 153M |
|---|---|---|---|---|---|
| Net income 2024 * | -157M | Net income 2025 * | -40M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 152M | Net cash position 2025 * | 295M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.86
x | P/E ratio 2025 * |
-3.07
x | Employees | 163 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.88% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProKidney Corp.
More recommendations
More press releases
| 1 day | +6.70% | ||
| 1 week | +15.74% | ||
| Current month | +15.74% | ||
| 1 month | +60.40% | ||
| 3 months | +92.74% | ||
| 6 months | +48.45% | ||
| Current year | +34.27% |
1 week
2.03
2.41
1 month
1.433.37
Current year
1.183.37
1 year
1.1213.51
3 years
1.1214.19
5 years
1.1214.19
10 years
1.1214.19
| Managers | Title | Age | Since |
|---|---|---|---|
Bruce Culleton
CEO | Chief Executive Officer | 57 | 23-07-16 |
James Coulston
DFI | Director of Finance/CFO | 48 | 21-12-31 |
Joseph Stavas
CTO | Chief Tech/Sci/R&D Officer | 69 | 19-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Doyle
BRD | Director/Board Member | 61 | 21-12-31 |
Brian Pereira
BRD | Director/Board Member | 65 | 21-12-31 |
John Maraganore
BRD | Director/Board Member | 60 | 22-08-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.53% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 2.39 | +6.70% | 384,987 |
| 24-05-06 | 2.24 | +1.82% | 294,364 |
| 24-05-03 | 2.2 | +2.33% | 575,060 |
| 24-05-02 | 2.15 | -0.46% | 351,401 |
| 24-05-01 | 2.16 | +4.60% | 518,175 |
End-of-day quote Nasdaq, May 06, 2024
More quotes
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patientâs own cells isolated from the patient intended for treatment. The Companyâs lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patientâs diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patientâs own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participantâs own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.39
USD
Average target price
4.2
USD
Spread / Average Target
+75.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.27% | 153M | |
| +21.74% | 46.4B | |
| -0.97% | 41.75B | |
| +47.07% | 41.37B | |
| -3.52% | 29.71B | |
| +11.12% | 26.01B | |
| -19.37% | 19.52B | |
| +31.18% | 12.43B | |
| -0.04% | 12.13B | |
| +0.39% | 12.18B |
- Stock Market
- Equities
- PROK Stock